Mitochondria as therapeutic targets for the treatment of malignant disease

Antioxidants and Redox Signaling

Volumn 15, Issue 12, 2011, Pages 2937-2949

  Fulda, Simone ^a   Kroemer, Guido ^b,c,d,e,f  

^a GOETHE UNIVERSITY   (Germany)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; ALPHA TOCOPHEROL SUCCINATE; BH3 PROTEIN; DEOXYGLUCOSE; DIAZEPAM; LONIDAMINE; METHYLTRIPHENYLPHOSPHONIUM; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; OBATOCLAX; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CANCER CELL; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL (TOPIC); COLON CANCER; DRUG DELIVERY SYSTEM; DYSPLASTIC NEVUS; FIBROSARCOMA; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; OLIGOMERIZATION; OUTER MEMBRANE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DELIVERY SYSTEMS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; MOLECULAR TARGETED THERAPY; NEOPLASMS; PERMEABILITY;

EID: 80155167845     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4078     Document Type: Review

References (133)

1. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, Xiao Y, Tse C, Frost DJ, Fesik SW, Rosenberg SH, Elmore SW, and Shoemaker AR. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66: 869-880, 2010.
2. Adams JM and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007.
3. Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F, and Batteux F. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 98: 236-244, 2006.
4. Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, Briand C, and Braguer D. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Letters 532: 256-260, 2002.
5. Azmi AS and Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 218: 13-21, 2009.
6. Belzacq AS, El Hamel C, Vieira HL, Cohen I, Haouzi D, Metivier D, Marchetti P, Brenner C, and Kroemer G. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 20: 7579-7587, 2001.
7. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, and Bost F. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475, 2010.
8. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J, and Boothman DA. An NQO1-and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci USA 104: 11832-11837, 2007.
9. Biasutto L, Mattarei A, Marotta E, Bradaschia A, Sassi N, Garbisa S, Zoratti M, and Paradisi C. Development of mitochondria-targeted derivatives of resveratrol. Bioorg Med Chem Lett 18: 5594-5597, 2008.
10. Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK, Schafer BW, Schrappe M, Stanulla M, and Bourquin JP. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 120: 1310-1323, 2010.
11. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, and Michelakis ED. A mitochondria-K + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11: 37-51, 2007.
12. Bouchier-Hayes L, Munoz-Pinedo C, Connell S, and Green DR. Measuring apoptosis at the single cell level. Methods 44: 222-228, 2008.
13. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, and Rosser CJ. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 68: 1223-1231, 2008.
14. Carvalho MA, Zecchin KG, Seguin F, Bastos DC, Agostini M, Rangel AL, Veiga SS, Raposo HF, Oliveira HC, Loda M, Coletta RD, and Graner E. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer 123: 2557-2565, 2008.
15. Chen S, Dai Y, Pei XY, and Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 29: 6149-6169, 2009.
16. Chipuk JE, Bouchier-Hayes L, and Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ 13: 1396-1402, 2006.
17. Constantinou C, Papas A, and Constantinou AI. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 123: 739-752, 2008.
18. Costantini P, Belzacq AS, Vieira HL, Larochette N, de Pablo MA, Zamzami N, Susin SA, Brenner C, and Kroemer G. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 19: 307-314, 2000.
19. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, and Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118: 3651-3659, 2008.
20. Cragg MS, Kuroda J, Puthalakath H, Huang DC, and Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4: 1681-1689; discussion 1690, 2007.
21. Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, Pellecchia M, Reed JC, Sarkar D, and Fisher PB. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci USA 108: 8785-8790, 2010.
22. Decaudin D, Castedo M, Nemati F, Beurdeley-Thomas A, De Pinieux G, Caron A, Pouillart P, Wijdenes J, Rouillard D, Kroemer G, and Poupon MF. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res 62: 1388-1393, 2002.
23. Degterev A, Boyce M, and Yuan J. A decade of caspases. Oncogene 22: 8543-8567, 2003.
24. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, and Schuetz F. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term followup. Ann Oncol 19: 2007-2011, 2008.
25. Dilda PJ, Decollogne S, Rossiter-Thornton M, and Hogg PJ. Para to ortho repositioning of the arsenical moiety of the angiogenesis inhibitor 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide results in a markedly increased cellular accumulation and antiproliferative activity. Cancer Res 65: 11729-11734, 2005.
26. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, and Hogg PJ. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3: 497-509, 2003.
27. Dong LF, Jameson VJ, Tilly D, Cerny J, Mahdavian E, Marin-Hernandez A, Hernandez-Esquivel L, Rodriguez-Enriquez S, Stursa J, Witting PK, Stantic B, Rohlena J, Truksa J, Kluckova K, Dyason JC, Ledvina M, Salvatore BA, Moreno-Sanchez R, Coster MJ, Ralph SJ, Smith RA, and Neuzil J. Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J Biol Chem 286: 3717-3728, 2011.
28. Dong LF, Jameson VJ, Tilly D, Prochazka L, Rohlena J, Valis K, Truksa J, Zobalova R, Mahdavian E, Kluckova K, Stantic M, Stursa J, Freeman R, Witting PK, Norberg E, Goodwin J, Salvatore BA, Novotna J, Turanek J, Ledvina M, Hozak P, Zhivotovsky B, Coster MJ, Ralph SJ, Smith RA, and Neuzil J. Mitochondrial targeting of alphatocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy. Free Radic Biol Med 50: 1546-1555, 2011.
29. Dong LF, Low P, Dyason JC, Wang XF, Prochazka L, Witting PK, Freeman R, Swettenham E, Valis K, Liu J, Zobalova R, Turanek J, Spitz DR, Domann FE, Scheffler IE, Ralph SJ, and Neuzil J. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 27: 4324-4335, 2008.
30. Dong LF, Swettenham E, Eliasson J, Wang XF, Gold M, Medunic Y, Stantic M, Low P, Prochazka L, Witting PK, Turanek J, Akporiaye ET, Ralph SJ, and Neuzil J. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Research 67: 11906-11913, 2007.
31. Dowling S, Cox J, and Cenedella RJ. Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids 44: 489-498, 2009.
32. Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, and Dorr R. Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 25: 1779-1784, 2007.
33. Fulda S. Tumor resistance to apoptosis. Int J Cancer 124: 511-515, 2009.
34. Fulda S and Debatin KM. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med Pediatr Oncol 35: 616-618, 2000.
35. Fulda S and Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006.
36. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer PH, Peter ME, and Debatin KM. Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57: 4956-4964, 1997.
37. Fulda S and Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 14: 885-890, 2009.
38. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, and Debatin KM. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 273: 33942-33948, 1998.
39. Fulda S, Susin SA, Kroemer G, and Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 58: 4453-4460, 1998.
40. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, and Kroemer G. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 12: 803-813, 2007.
41. Gatenby RA and Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899, 2004.
42. Gledhill JR, Montgomery MG, Leslie AG, and Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci USA 104: 13632-13637, 2007.
43. Gogvadze V, Orrenius S, and Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18: 165-173, 2008.
44. Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T, Bronner V, Notcovich A, Shoshan-Barmatz V, and Flescher E. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27: 4636-4643, 2008.
45. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, and Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFRdependent lung adenocarcinomas. PLoS Med 4: e294, 2007.
46. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 100: 57-70, 2000.
47. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, and Rudin CM. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68: 2321-2328, 2008.
48. Harrison LR, Micha D, Brandenburg M, Simpson KL, Morrow CJ, Denneny O, Hodgkinson C, Yunus Z, Dempsey C, Roberts D, Blackhall F, Makin G, and Dive C. Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. J Clin Invest 121: 1075-1087, 2011.
49. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, and Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8: 311-321, 2005.
50. Heidari N, Hicks MA, and Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 1: e76, 2010.
51. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, and Lock RB. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 77: 483-494, 2010.
52. Huang P, Feng L, Oldham EA, Keating MJ, and Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407: 390-395, 2000.
53. Huang S, Okumura K, and Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 15: 150-159, 2009.
54. Huang S and Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 68: 2944-2951, 2008.
55. Juarez JC, Manuia M, Burnett ME, Betancourt O, Boivin B, Shaw DE, Tonks NK, Mazar AP, and Donate F. Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA 105: 7147-7152, 2008.
56. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB, and Reynolds CP. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110: 2057-2066, 2007.
57. Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, and Reed JC. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 111: 3211-3219, 2008.
58. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, and Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 46: 4259-4264, 2003.
59. Knowles LM, Yang C, Osterman A, and Smith JW. Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem 283: 31378-31384, 2008.
60. Kohl TM, Hellinger C, Ahmed F, Buske C, Hiddemann W, Bohlander SK, and Spiekermann K. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21: 1763-1772, 2007.
61. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi Y-X, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, and Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388, 2006.
62. Kroemer G and de The H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 91: 743-745, 1999.
63. Kroemer G, Galluzzi L, and Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99-163, 2007.
64. Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, and Maekawa T. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Ablpositive leukemia. Cell Death Differ 14: 1667-1677, 2007.
65. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DCS, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, and Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103: 14907-14912, 2006.
66. Kutuk O and Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 68: 7985-7994, 2008.
67. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK, and Hassinen IE. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61: 1255-1262, 2002.
68. Liby KT, Yore MM, and Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7: 357-369, 2007.
69. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC, and Jia L. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 111: 2797-2805, 2008.
70. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, and Somer B. An open-label, multicenter, phase I/II study of singleagent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 15: 3172-3176, 2009.
71. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, and Smith MA. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 1181-1189, 2008.
72. Lockshin RA, and Zakeri Z. Cell death in health and disease. J Cell Mol Med 11: 1214-1224, 2007.
73. Lu J, Chew EH, and Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 104: 12288-12293, 2007.
74. Lynn A and Jones L. Gossypol and some other terpenoids, flavonoids, and phenols that affect quality of cottonseed protein. Am Oil Chemists Soc 56: 727-730, 1979.
75. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, and Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and Lbuthionine-sulfoximine. Cell Death Differ 11: 737-746, 2004.
76. Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Mereau-Richard C, Costantini P, Metivier D, Susin SA, Kroemer G, and Formstecher P. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 59: 6257-6266, 1999.
77. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, Huang DCS, and Kile BT. Programmed anuclear cell death delimits platelet life span. Cell 128: 1173-1186, 2007.
78. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, Grigg AP, Seymour JF, Szer J, Huang DC, and Roberts AW. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23: 2034-2041, 2009.
79. Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC, and Roberts AW. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 105: 17961-17966, 2008.
80. Meng RD and El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res 262: 154-169, 2001.
81. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, and Petruk KC. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2: 31ra34, 2010.
82. Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, and Shellman YG. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol 129: 964-971, 2009.
83. Montesinos P, Rayon C, Vellenga E, Brunet S, Gonzalez J, Gonzalez M, Holowiecka A, Esteve J, Bergua J, Gonzalez JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Perez I, Perez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, and Sanz MA. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 117: 1799-1805, 2011.
84. Murias M, Luczak MW, Niepsuj A, Krajka-Kuzniak V, Zielinska-Przyjemska M, Jagodzinski PP, Jager W, Szekeres T, and Jodynis-Liebert J. Cytotoxic activity of 3,3,4,4,5,5-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol In Vitro 22: 1361-1370, 2008.
85. Murphy MP. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol 15: 326-330, 1997.
86. Neupert W and Herrmann JM. Translocation of proteins into mitochondria. Annu Rev Biochem 76: 723-749, 2007.
87. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Belec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, and Shore GC. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104: 19512-19517, 2007.
88. Notario B, Zamora M, Vinas O, and Mampel T. All-transretinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition. Mol Pharmacol 63: 224-231, 2003.
89. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, and Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113: 299-305, 2009.
90. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, and Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681, 2005.
91. Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, Dutrillaux B, Andrieu JM, and Delattre JY. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 63: 81-86, 2003.
92. Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, and Krug LM. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 66: 1079-1085, 2010.
93. Palmeira CM and Wallace KB. Benzoquinone inhibits the voltage-dependent induction of the mitochondrial permeability transition caused by redox-cycling naphthoquinones. Toxicol Appl Pharmacol 143: 338-347, 1997.
94. Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, and O'Connor OA. The BH3-only mimetic ABT-737 synergizes the anti-neoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112: 2906-2916, 2008.
95. Patterson SD, Spahr CS, Daugas E, Susin SA, Irinopoulou T, Koehler C, and Kroemer G. Mass spectrometric identification of proteins released from mitochondria undergoing permeability transition. Cell Death Differ 7: 137-144, 2000.
96. Perez-Galan P, Roue G, Villamor N, Campo E, and Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109: 4441-4449, 2007.
97. Pervaiz S and Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 11: 2851-2897, 2009.
98. Petronilli V, Costantini P, Scorrano L, Colonna R, Passamonti S, and Bernardi P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. J Biol Chem 269: 16638-16642, 1994.
99. Prochazka L, Dong LF, Valis K, Freeman R, Ralph SJ, Turanek J, and Neuzil J. Alpha-tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. Apoptosis 15: 782-794, 2010.
100. Roberts AW, Wilson W, Gandhi L, O'Connor OA, Rudin CM, Brown JR, Xiong H, Chiu Y, Enschede S, and Krivoshik AP. Ongoing phase I studies of ABT-263: mitigating Bcl-XL induced thrombocytopenia with lead-in and continuous dosing. J Clin Oncol (Meeting Abstr) 27: 3505, 2009.
101. Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, and Flescher E. Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 65: 1984-1993, 2005.
102. Salti GI, Kichina JV, Das Gupta TK, Uddin S, Bratescu L, Pezzuto JM, Mehta RG, and Constantinou AI. Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent. Melanoma Res 11: 99-104, 2001.
103. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, and Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120: 142-156, 2010.
104. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, and Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14: 8295-8301, 2008.
105. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, and Dixit VM. Deubiquitinase USP9 stabilizes MCL1 and promotes tumour cell survival. Nature 463: 103-107, 2010.
106. Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, Jansen B, and Kodym R. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 114: 935-940, 2000.
107. Selzer E, Thallinger C, Hoeller C, Oberkleiner P, Wacheck V, Pehamberger H, and Jansen B. Betulinic acid-induced Mcl-1 expression in human melanoma-mode of action and functional significance. Mol Med 8: 877-884, 2002.
108. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, and Spitz DR. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 67: 3364-3370, 2007.
109. Smoot RL, Blechacz BR, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, and Gores GJ. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res 70: 1960-1969, 2010.
110. Song JH, Kandasamy K, and Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 283: 25003-25013, 2008.
111. Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, and Blackburn AC. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 120: 253-260, 2010.
112. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, and Roth W. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 6646-6656, 2008.
113. Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H, Elmore SW, Kroeger PE, Tse C, Rosenberg SH, and Anderson MG. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 9: 545-557, 2010.
114. Thurnher D, Turhani D, Pelzmann M, Wannemacher B, Knerer B, Formanek M, Wacheck V, and Selzer E. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head & Neck 25: 732-740, 2003.
115. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, and Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241-252, 2006.
116. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, and Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109: 5430-5438, 2007.
117. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, and Elmore SW. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428, 2008.
118. Van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, and Huang DCS. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399, 2006.
119. Vandenabeele P, Galluzzi L, Vanden Berghe T, and Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 11: 700-714, 2010.
120. Vestweber D, and Schatz G. DNA-protein conjugates can enter mitochondria via the protein import pathway. Nature 338: 170-172, 1989.
121. Volate SR, Kawasaki BT, Hurt EM, Milner JA, Kim YS, White J, and Farrar WL. Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumorinitiating cells. Mol Cancer Ther 9: 461-470, 2010.
122. Warburg O, Posener K, and Negelein E. Über den Stoffwechsel der Tumoren. Biochemische Zeitschrift 152: 319-344, 1924.
123. Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, and Hughes J. DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm Res 15: 334-337, 1998.
124. Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, Peart MJ, Newbold A, Lindemann RK, and Johnstone RW. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 113: 1982-1991, 2009.
125. Wick W, Grimmel C, Wagenknecht B, Dichgans J, and Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther 289: 1306-1312, 1999.
126. Wong JY, Huggins GS, Debidda M, Munshi NC, and De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 109: 394-402, 2008.
127. Xiao D, Lew KL, Zeng Y, Xiao H, Marynowski SW, Dhir R, and Singh SV. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 27: 2223-2234, 2006.
128. Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, Yamashita K, Kobayashi H, Kikuchi H, and Harashima H. MITO-Porter: a liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta 1778: 423-432, 2008.
129. Yecies D, Carlson NE, Deng J, and Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115: 3304-3313, 2010.
130. Yousif LF, Stewart KM, Horton KL, and Kelley SO. Mitochondria-penetrating peptides: sequence effects and model cargo transport. Chembiochem 10: 2081-2088, 2009.
131. Yousif LF, Stewart KM, and Kelley SO. Targeting mitochondria with organelle-specific compounds: strategies and applications. Chembiochem 10: 1939-1950, 2009.
132. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, Iciek LA, Morgan SJ, Nasarre MC, Nelson R, Preusser LC, Reinhart GA, Smith ML, Rosenberg SH, Elmore SW, and Tse C. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14: 943-951, 2007.
133. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, and Formelli F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17-25, 2002.